Welcome to our dedicated page for Cv Sciences news (Ticker: CVSI), a resource for investors and traders seeking the latest updates and insights on Cv Sciences stock.
CV Sciences, Inc. (OTCQB:CVSI) generates a steady stream of news as a consumer wellness company specializing in hemp extracts, nutraceuticals, and plant-based foods. Company announcements frequently cover financial results, product launches, regulatory developments, and capital markets activity, offering investors and observers insight into how the business is evolving across its wellness and plant-based platforms.
Regular earnings releases detail quarterly and annual performance, including product sales, gross margin trends, operating income or loss, cash balances, and non-GAAP measures such as Adjusted EBITDA. These updates often highlight the contribution of new products launched since early 2023 and discuss how state and federal regulatory environments for CBD affect B2B and B2C sales.
CV Sciences also issues news on new product introductions and brand extensions. Recent examples include the Ignite men’s performance formula under its wellness portfolio, the +PlusHLTH™ cannabinoid-free supplement line, expanded +PlusCBD™ sleep, calm, reserve, and pet products, and the launch of Lunar Fox, a plant-based company offering vegan alternatives to traditional animal-based proteins. These stories illustrate the company’s focus on innovation and diversification across supplements and plant-based foods.
Another recurring theme in CVSI news is regulatory and policy engagement. The company has publicly commented on federal actions related to CBD research and potential Medicare and Medicaid reimbursement for CBD products, as well as state-level legislation such as Texas Senate Bill 3. In addition, SEC Form 8-K filings and related press releases describe material financing agreements, secured promissory notes, and other capital structure developments.
For readers tracking CVSI, this news feed provides context on the company’s operating performance, product pipeline, regulatory posture, and financing activities. Returning to this page allows users to follow how CV Sciences’ hemp-derived wellness, supplement, and plant-based food strategies are reflected in its ongoing disclosures.
CV Sciences (OTCQB:CVSI) has acquired Elevated Softgels, a GMP-certified and FDA-registered manufacturer of encapsulated softgels and tinctures. Elevated Softgels' flexible production capabilities allow CV Sciences to in-source production of key products, potentially leading to significant cost savings. The acquisition involves a total consideration of up to $1,000,000, including a cash payment of $100,000, shares valued at $700,000, and up to $200,000 in performance-based earn-outs. Elevated Softgels, now a wholly-owned subsidiary, is expected to contribute to immediate growth and long-term shareholder value.
CV Sciences, Inc. will announce its first-quarter 2024 financial results on May 14, 2024. The company specializes in hemp extracts and natural products. The conference call with the investment community will take place at 7:00 a.m. Pacific Time on the same day. Interested investors can access the webcast on the Investor Relations section of the company's website, and a telephone replay will be available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.